科源制药
(301281)
| 流通市值：25.62亿 | | | 总市值：40.29亿 |
| 流通股本：6885.20万 | | | 总股本：1.08亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 267,304,173.29 | 176,752,879.22 | 568,547,454.88 | 325,219,461.97 |
| 应收票据及应收账款 | 54,000,218.57 | 64,233,729.39 | 93,070,667.96 | 62,531,614.43 |
| 其中：应收票据 | 8,044,575.74 | 18,316,008.03 | 16,767,533.25 | 19,132,864.13 |
| 应收账款 | 45,955,642.83 | 45,917,721.36 | 76,303,134.71 | 43,398,750.3 |
| 应收款项融资 | 2,672,896.69 | 16,854,006.64 | 18,403,898.68 | 13,314,754.92 |
| 预付款项 | 12,730,997.51 | 10,200,963.79 | 15,478,245.5 | 4,880,931.37 |
| 其他应收款合计 | 2,926,156.52 | 1,922,046.9 | 4,903,564.94 | 651,090.7 |
| 其中:应收利息 | - | - | 84,552.11 | - |
| 存货 | 103,939,818.19 | 100,508,214.39 | 99,354,540.88 | 108,054,744.66 |
| 其他流动资产 | 13,602,924.61 | 15,499,755.31 | 287,872.19 | 213,592,840.69 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 643,859,810.97 | 710,579,541.14 | 830,437,539.4 | 878,788,621.84 |
| 非流动资产: | | | | |
| 长期股权投资 | 184,007,854.35 | 183,393,682 | 183,080,078.52 | 183,080,078.52 |
| 其他权益工具投资 | 2,399,595.96 | 1,000,000 | 1,000,000 | 1,000,000 |
| 固定资产 | 296,915,139.6 | 304,019,177.54 | 301,496,583.4 | 302,049,481.19 |
| 在建工程 | 181,435,014.11 | 124,722,930.81 | 12,770,631.14 | 12,154,064.81 |
| 无形资产 | 88,956,234.23 | 90,050,722.32 | 54,251,807.92 | 46,018,281.25 |
| 商誉 | 1,820,994.04 | 1,820,994.04 | 1,820,994.04 | - |
| 长期待摊费用 | 3,697,791.82 | 2,221,230.01 | 2,730,678.61 | 728,565.5 |
| 递延所得税资产 | 2,473,425.48 | 2,655,436.19 | 2,673,457.45 | 2,924,149.53 |
| 其他非流动资产 | 59,102,301.17 | 48,148,006.3 | 113,607,869.05 | 43,224,731.37 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 820,808,350.76 | 758,032,179.21 | 673,432,100.13 | 591,179,352.17 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,464,668,161.73 | 1,468,611,720.35 | 1,503,869,639.53 | 1,469,967,974.01 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 53,267,584.5 | 47,501,834.47 | 60,852,111.84 | 50,182,366.27 |
| 应付账款 | 53,267,584.5 | 47,501,834.47 | 60,852,111.84 | 50,182,366.27 |
| 合同负债 | 2,388,856.12 | 2,929,114.25 | 2,586,106.41 | 3,500,711.09 |
| 应付职工薪酬 | 9,926,988.48 | 8,846,295.25 | 8,392,431.89 | 7,736,838.42 |
| 应交税费 | 907,825.62 | 3,646,949.16 | 5,880,705.75 | 2,086,210.17 |
| 其他应付款合计 | 25,588,182.82 | 26,565,582.43 | 32,430,778.35 | 33,850,749.94 |
| 其他流动负债 | 7,056,805.93 | 16,271,031.68 | 15,364,312.44 | 13,786,213.95 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 99,136,243.47 | 105,760,807.24 | 125,506,446.68 | 111,143,089.84 |
| 非流动负债: | | | | |
| 递延收益 | 10,101,048.31 | 10,631,014.41 | 9,221,742.7 | 10,532,184.54 |
| 递延所得税负债 | 17,953,141.95 | 18,726,628.06 | 17,310,598.79 | 17,252,452.09 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 28,054,190.26 | 29,357,642.47 | 26,532,341.49 | 27,784,636.63 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 127,190,433.73 | 135,118,449.71 | 152,038,788.17 | 138,927,726.47 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 108,290,000 | 108,290,000 | 108,290,000 | 108,290,000 |
| 资本公积 | 906,672,990.8 | 906,672,990.8 | 909,969,126.86 | 909,969,126.86 |
| 专项储备 | 2,158,354.86 | 1,702,174.47 | 970,306.64 | 477,950.92 |
| 盈余公积 | 46,773,352.27 | 46,773,352.27 | 46,773,352.27 | 46,773,352.27 |
| 未分配利润 | 272,725,893.74 | 269,133,919.49 | 284,852,088.07 | 265,529,817.49 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,336,620,591.67 | 1,332,572,437.03 | 1,350,854,873.84 | 1,331,040,247.54 |
| 少数股东权益 | 857,136.33 | 920,833.61 | 975,977.52 | - |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,337,477,728 | 1,333,493,270.64 | 1,351,830,851.36 | 1,331,040,247.54 |
| 负债和股东权益合计 | 1,464,668,161.73 | 1,468,611,720.35 | 1,503,869,639.53 | 1,469,967,974.01 |
| 公告日期 | 2024-10-25 | 2024-08-20 | 2024-04-22 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |